Core Insights - MannKind Corporation is scheduled to present business updates at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026, at 11:20 a.m. ET [1] - The presentation will be available via webcast on MannKind's website, with recorded versions accessible for approximately 90 days post-conference [1] Company Overview - MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative, patient-centric solutions [2] - The company specializes in treatments for cardiometabolic and orphan lung diseases, addressing serious unmet medical needs such as diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease [2] Expertise and Approach - MannKind has deep expertise in drug-device combinations, aiming to deliver therapies that integrate seamlessly into patients' daily lives [3]

Core Viewpoint - MannKind Corporation is set to release its fourth quarter and full year 2025 financial results on February 26, 2026, before market opening [1] Group 1: Financial Results Announcement - The financial results will be reviewed in a webcast starting at 9:00 a.m. Eastern Time on the same day [2] - The webcast will be accessible via MannKind's investor relations website, with a replay available for approximately 90 days [2] Group 2: Company Overview - MannKind Corporation focuses on transforming chronic disease care through innovative, patient-centric solutions, particularly in cardiometabolic and orphan lung diseases [3] - The company develops and commercializes treatments for serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease [3] Group 3: Expertise and Approach - MannKind has deep expertise in drug-device combinations, aiming to deliver therapies that integrate seamlessly into patients' daily lives [4]

Core Viewpoint - MannKind Corporation is set to present updates at the Jefferies London Healthcare Conference on November 19, 2025, highlighting its focus on innovative solutions for chronic diseases [1]. Company Overview - MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions [3]. - The company focuses on cardiometabolic and orphan lung diseases, developing treatments for serious unmet medical needs such as diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease [3]. Product Development Focus - MannKind specializes in drug-device combinations, aiming to deliver therapies that integrate seamlessly into patients' daily lives [4].